Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Alimera Sciences
(NASDAQ:ALIM)
Intraday
$3.80
0.21
[5.85%]
After-Hours
$3.80
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.80
0.21
[5.85%]
At close: Apr 9
$3.80
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Alimera Sciences Stock (NASDAQ:ALIM)
Alimera Sciences Stock (NASDAQ: ALIM)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, March 25, 2024
Maxim Group Initiates Coverage On Alimera Sciences with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk
-
Mar 25, 2024, 8:03AM
Tuesday, March 19, 2024
Alimera Announces First Patient Randomized In Radiation Retinopathy Trial Being Conducted By The DRCR Retina Network
Benzinga Newsdesk
-
Mar 19, 2024, 8:05AM
Friday, March 08, 2024
HC Wainwright & Co. Maintains Buy on Alimera Sciences, Raises Price Target to $6
Benzinga Newsdesk
-
Mar 8, 2024, 1:01PM
Thursday, March 07, 2024
Alimera Sciences Expects 2024 Revenue Over $105M Vs. $103.66M Consensus, And Greater Than 20% Adjusted EBITDA Margin
Benzinga Newsdesk
-
Mar 7, 2024, 7:40AM
Alimera Sciences Q4 EPS $(0.07) Up From $(0.54) YoY, Sales $26.31M Beat $24.34M Estimate
Benzinga Newsdesk
-
Mar 7, 2024, 7:32AM
Earnings Scheduled For March 7, 2024
Benzinga Insights
-
Mar 7, 2024, 4:49AM
Wednesday, March 06, 2024
A Preview Of Alimera Sciences's Earnings
Benzinga Insights
-
Mar 6, 2024, 2:02PM
Thursday, February 08, 2024
The UK National Institute For Health And Care Excellence Issues Final Draft Guidance To Provide Patients With A Natural Lens Being Treated For Chronic Diabetic Macular Edema Access To ILUVIEN
Benzinga Newsdesk
-
Feb 8, 2024, 8:01AM
Thursday, January 04, 2024
Alimera Completes Recruitment For The Synchronicity Study
Benzinga Newsdesk
-
Jan 4, 2024, 8:15AM
Tuesday, January 02, 2024
Alimera Sciences Appoints Elliot Maltz As CFO Effective Immediately; Succeeds Russell Skibsted
Benzinga Newsdesk
-
Jan 2, 2024, 8:12AM
Wednesday, November 29, 2023
Chief Financial Officer & SVP at Alimera Sciences Acquires Company Stock Options Worth 50,000 Shares
Benzinga Insights
-
Nov 29, 2023, 10:01AM
Chief Operating Officer & SVP at Alimera Sciences Acquires Company Stock Options Worth 147,000 Shares
Benzinga Insights
-
Nov 29, 2023, 10:01AM
Alimera Sciences Chief Marketing Officer & SVP Awarded $302K Worth of Stock Options
Benzinga Insights
-
Nov 29, 2023, 10:01AM
Tuesday, October 31, 2023
Alimera Announces Scientific Data Highlighting ILUVIEN To Be Presented At The American Academy Of Ophthalmology
Benzinga Newsdesk
-
Oct 31, 2023, 8:08AM
Thursday, October 26, 2023
Earnings Scheduled For October 26, 2023
Benzinga Insights
-
Oct 26, 2023, 7:20AM
Alimera Sciences Q3 EPS $(0.06) Vs $(0.75) Last Year, Sales $23.36M Beat $22.72M Estimate
Benzinga Newsdesk
-
Oct 26, 2023, 7:06AM
Wednesday, October 11, 2023
Alimera Announces Multiple Presentations Highlighting ILUVIEN And YUTIQ Data At Retina Society Annual Congress
Benzinga Newsdesk
-
Oct 11, 2023, 8:07AM
Thursday, October 05, 2023
Board Member at Alimera Sciences Acquires Company Stock Options Worth 50,000 Shares
Benzinga Insights
-
Oct 5, 2023, 11:00AM
Tuesday, October 03, 2023
On October 3, 2023, Alimera Sciences Appointed Jason Werner As The Company's Chief Operating Officer, Effective October 2: 8K
Benzinga Newsdesk
-
Oct 3, 2023, 7:09AM
Monday, August 14, 2023
The Latest Analyst Ratings for Alimera Sciences
Benzinga Insights
-
Aug 14, 2023, 3:00PM
HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $5 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 6:39AM
Thursday, August 10, 2023
Alimera Sciences Q2 EPS $(1.32) Misses $0.06 Estimate, Sales $17.54M Miss $20.36M Estimate
Benzinga Newsdesk
-
Aug 10, 2023, 7:32AM
Earnings Scheduled For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 6:59AM
Wednesday, August 09, 2023
Preview: Alimera Sciences's Earnings
Benzinga Insights
-
Aug 9, 2023, 2:02PM
Monday, June 12, 2023
Alliance Global Partners Upgrades Alimera Sciences: Here's What You Need To Know
Benzinga Insights
-
Jun 12, 2023, 1:00PM
Alimera Sciences shares are trading higher after Alliance Global Partners upgraded the stock from Neutral to Buy and raised its price target from $4.5 to $8.
Benzinga Newsdesk
-
Jun 12, 2023, 12:20PM
Benzinga's Top Ratings Upgrades, Downgrades For June 12, 2023
Benzinga Insights
-
Jun 12, 2023, 11:00AM
10 Short Squeeze Stocks To Watch: Getty Images, Intuitive Machines, Wearable Devices & More
Chris Katje
-
Jun 12, 2023, 10:34AM
Expert Ratings for Alimera Sciences
Benzinga Insights
-
Jun 12, 2023, 10:03AM
Alliance Global Partners Upgrades Alimera Sciences to Buy, Raises Price Target to $8
Benzinga Newsdesk
-
Jun 12, 2023, 8:18AM
Friday, June 09, 2023
On June 7, 2023, Nasdaq Notified Alimera Sciences Inc Is In Compliance With Nasdaq Listing Rules
Happy Mohamed
-
Jun 9, 2023, 9:27AM
Thursday, May 25, 2023
HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $5 Price Target
Benzinga Newsdesk
-
May 25, 2023, 9:37AM
Wednesday, May 24, 2023
Alimera Completes Recruitment for its Landmark NEW DAY Study
Benzinga Newsdesk
-
May 24, 2023, 8:14AM
Friday, May 19, 2023
Why Foot Locker Shares Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Lisa Levin
-
May 19, 2023, 1:21PM
4 Analysts Have This to Say About Alimera Sciences
Benzinga Insights
-
May 19, 2023, 1:01PM
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights
-
May 19, 2023, 9:06AM
Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Lisa Levin
-
May 19, 2023, 8:17AM
HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $5
Benzinga Newsdesk
-
May 19, 2023, 6:20AM
Thursday, May 18, 2023
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga Insights
-
May 18, 2023, 1:31PM
Why Monro Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin
-
May 18, 2023, 1:19PM
US Stocks Mixed; Jobless Claims Drop More than Projected
Lisa Levin
-
May 18, 2023, 9:56AM
Alimera Sciences shares are trading higher after the company announced it acquired U.S. commercial rights to YUTIQ.
Benzinga Newsdesk
-
May 18, 2023, 9:07AM
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
May 18, 2023, 9:07AM
EyePoint Pharmaceuticals Announces Sale Of YUTIQ To Alimera Sciences For $82.5M Cash Plus Royalties
Benzinga Newsdesk
-
May 18, 2023, 7:04AM
EyePoint Pharma Offloads Its Commercially-Available Eye Implant For $82.5M Plus Royalties
Vandana Singh
-
May 18, 2023, 7:02AM
Tuesday, May 16, 2023
HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $9 Price Target
Benzinga Newsdesk
-
May 16, 2023, 12:03PM
Monday, May 15, 2023
Alimera Sciences Q1 EPS $(0.71) Misses $(0.51) Estimate, Sales $13.55M Beat $12.30M Estimate
Benzinga Newsdesk
-
May 15, 2023, 7:52AM
Earnings Scheduled For May 15, 2023
Benzinga Insights
-
May 15, 2023, 5:32AM
Thursday, April 20, 2023
Alimera Data Will Feature in Scientific Programming at Upcoming Annual Congress
Benzinga Newsdesk
-
Apr 20, 2023, 8:02AM
Monday, April 03, 2023
HC Wainwright & Co. Reiterates Buy on Alimera Sciences, Maintains $9 Price Target
Benzinga Newsdesk
-
Apr 3, 2023, 6:21AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch